Related Experiment Video
Updated: Jun 29, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Suppression of estrogenic activity of 17-beta-estradiol by beta-cyclodextrin
Kyoko Oishi1, Keita Toyao, Yoshihiro Kawano
1Department of Civil Engineering, Graduate School of Engineering, Kyushu University, Fukuoka, Japan. ohishi@civil.kyushu-u.ac.jp
Abstract:
The suppressive effects of cyclodextrins (CDs) on the strong estrogenic activity of 17beta-estradiol (E2) in water environments were investigated in this study. Cyclodextrins are doughnut-shaped molecules that possess a hydrophobic cavity and a hydrophilic exterior. The cavity can incorporate nonpolar molecules as guests to form inclusion complexes. beta-CD and 2-hydroxypropyl-beta-CD (HP-beta-CD) were the most successful in forming a complex with E2 and improving its low aqueous solubility. The E2/CDs complexes bound to the estrogen receptor in a cell-free system as determined by ELISA and suppressed the hormone activities as measured by a yeast two-hybrid assay. These results indicate that hydrophobic E2 is easily transported through the lipid zone of the plasma membrane into the target cell and can bind to the nuclear receptor. However, the hydrophilic E2/beta-CD and E2/HP-beta-CD complexes do not penetrate the membrane. Therefore, these CDs are able to suppress the hormone activity of E2 through complex formation.
Related Concept Videos
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Inhibition of Cdk Activity
Inhibition of CDK Activity
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
